Expert Interview
Cancer-associated fibroblasts (CAFs) as a promising therapeutic target
Ticker(s): CLVSAn cancer immunologist with a focus in cancer-associated fibroblasts
CAFs have been known to be a promising therapeutic target, but drugs that target CAFs have shown limited clinical success. Why is that the case?
Added By: usere23d23fRecent studies show there are subpopulations of CAFs based on function. How can this finding play a role in targeting CAFs?
Added By: usere23d23fThere are approaches that are used to identify markers for subpopulations of CAFs, but limited efforts to translate therapies targeting subpopulations of CAFs. Why is that so?
Added By: usere23d23fWhat are the challenges in studying CAFs in preclincal models?
Added By: usere23d23fCAFs has been shown predominately to be tumor-promoting. However, new studies show certain CAFs can be tumor-suppressive. What are your thoughts on this concept of CAFs being tumor-suppressive?
Added By: usere23d23fWhat are the disadvantages/advantages between therapies directly targeting CAFs (depleting CAFs) vs indirectly targeting CAFS (interfering pathways)?
Added By: usere23d23fWhere in the CAF field that will make the next biggest impact in context of developing targeted therapies?
Added By: usere23d23fAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
